Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic by Dwaine F. EmerichCentral Nervous System Diseases: Innovative Animal Models from Lab to Clinic by Dwaine F. Emerich

Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic

EditorDwaine F. Emerich, Reginald L. Dean III, Paul R. Sanberg

Paperback | November 19, 2010

Pricing and Purchase Info

$338.96 online 
$388.95 list price save 12%
Earn 1,695 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Prominent experimentalists critically review the animal models widely used in developing powerful new therapies for central nervous system diseases. Coverage includes novel uses of animal models of Alzheimer's, Parkinson's, and Huntington's diseases, and studies of aging. Techniques that rely heavily on behavioral analyses, as well as models developed from infusions of neurotoxins and from advances in molecular biology, are thoroughly explicated, as are models developed for more acute neurological conditions, including traumatic brain injury and stroke. Comprehensive and authoritative, Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic offers neuroscientists, pharmacologists, and interested clinicians a unique survey of the most productive animal models of the leading neurological diseases currently employed to develop today's innovative drug therapies.
Title:Central Nervous System Diseases: Innovative Animal Models from Lab to ClinicFormat:PaperbackDimensions:527 pagesPublished:November 19, 2010Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1617371521

ISBN - 13:9781617371523

Look for similar items by category:


Table of Contents

Part I. Aging and Alzheimer's Disease. The Cholinergic Hypothesis a Generation Later: Perspectives Gained on the Use and Integration of Animal Models, Raymond T. Bartus. Patterns of Cognitive Decline in the Aged Rhesus Monkey, Mark B. Moss, Ronald J. Killiany, and James G. Herndon. Cholinergic Lesions as a Model of Alzheimer's Disease: Effects of Nerve Growth Factor, James M. Conner and Mark H. Tuszynski. The Immunolesioned Animal as a Model of Transmitter Dysfunction, Gary L. Wenk. An Intracerebral Tumor Necrosis Factor-a Infusion Model for Inflammation in Alzheimer's Disease, Kimberly B. Bjugstad and Gary W. Arendash. The Senescence-Accelerated Mouse as a Possible Animal Model of Senile Dementia, Yasuyuki Nomura, Yasunobu Okuma, and Yoshihisa Kitamura. Transgenic Mice Overexpressing Presenilin cDNAs: Phenotype and Utility in the Modeling of Alzheimer's Disease, Karen Duff. Part II. Parkinson's Disease. Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism: Optimizing Behavioral Assessment of Outcome, Timothy Schallert and Jennifer L. Tillerson. Development of Behavioral Outcome Measures for Preclinical Parkinson's Research, Mark D. Lindner. Behavioral Assessment in the Unilateral Dopamine-Depleted Marmoset, L. E. Annett, R. E. Smyly, J. M. Henderson, R. M. Cummings, A. L. Kendall, and S. B. Dunnett. Molecules for Neuroprotection and Regeneration in Animal Models of Parkinson's Disease, O. Isacson, L. C. Costantini, and W. R. Galpern. Antisense Knockdown of Dopamine Receptors, Simranjit Kaur and Ian Creese. Is Trophic Factor Gene Disruption a "Knockout" Model for Parkinson's Disease?, Ann-Charlotte Granholm and Barry Hoffer. Part III. Huntington's Disease. Operant Analysis of Striatal Dysfunction, Peter J. Brasted, Màté D. Döbrössy, Dawn M. Eagle, Falguni Nathwani, Trevor W. Robbins, and Stephen B. Dunnett. Intrastriatal Injections of Quinolinic Acid as a Model for Developing Neuroprotective Strategies in Huntington's Disease, Dwaine F. Emerich. Systemic Administration of 3-Nitropropionic Acid: A New Model of Huntington's Disease in Rat, Emmanuel Brouillet, Philippe Hantraye, and M. Flint Beal. Replicating Huntington Disease's Phenotype in Nonhuman Primates, Philippe Hantraye, Stéphane Palfi, Vincent Mittoux, Caroline Dautry, Françoise Condé, and Emmanuel Brouillet. Transgenic Mouse Models of Huntington's Disease, Gillian P. Bates, Laura Mangiarini, and Stephen W. Davies. Part IV. Traumatic Brain Injury and Stroke. Rigid Indentation Models of Traumatic Brain Injury in the Rat, Richard L. Sutton. Rodent Ischemia Models of Embolism and Ligation of the Middle Cerebral Artery: Clinical Relevance to Treatment Strategies of Stroke, Cesario V. Borlongan, Hitoo Nishino, Yun Wang, and Paul R. Sanberg. A Primate Model of Hypertensive Cerebrovascular Disease, Mark B. Moss. Part V. Innovations Leading to Clinical Therapy. Nictotinic Therapeutics for Tourette Syndrome and Other Neuropsychiatric Disorders: From Laboratory to Clinic, R. Doug Shytle, Archie A. Silver, Mary B. Newman, and Paul R. Sanberg. Neural Grafting for Parkinson's and Huntington's Disease, Ben Roitberg, Peter Shin, Joseph Sramek, and Jeffrey H. Kordower. Future Prospects of Gene Therapy for Treating CNS Diseases, Daniel A. Peterson, Jasodhara Ray, and Fred H. Gage. Index.

Editorial Reviews

"This book is an elegant survey of primate and nonprimate models for the most important of the CNS diseases, examining the prospects of treatment from various (slightly) promising drug therapies to the newest forms of fetal-tissue grafting. But more than that, the editors have compiled a paradigmatic study on the critical need for animal experimentation for the elucidation and treatment of human disease. Each chapter points out how animal models provided the only nonsuperficial insight available on various CNS syndromes, and perhaps equally important, how animals served as models for verification of theories and as test subjects for potential treatments. "- Modern Drug Discovery"...the contributions contained in this monograph represent a serious attempt by many of the most important researchers in neuroscience to critically assess the most useful animal models in development today... this is an excellent volume which will be an essential reading for all experimental neuropharmacologists and a constant source of reference to both clinical and basic psychopharmacologists. The editors are to be congratulated for gathering together such an authoritative group of authors who have explained their research interests in an easily accessible way." - Human Phychopharmacology